Date: 2018-09-27
Type of information: Production agreement
Compound: orticumab (BI-204)
Company: BioInvent (Sweden) Cardiovax (USA - CA)
Therapeutic area: Inflammatory diseases - Technology Services
Type agreement: production - manufacturing
Action mechanism: monoclonal antibody
Disease:
Details:
- • On September 27, 2018, BioInvent International announced that following a global licensing agreement it has signed a manufacturing agreement with CardioVax for orticumab, previously known as BI-204. CardioVax, a privately held company in California, is advancing the treatment of inflammatory diseases with novel antibody therapeutics.
Financial terms:
- Under the terms of the agreement, Bioinvent is expected to generate manufacturing revenue of approximately $ 3.0 million in the near term, mainly in 2019. Furthermore, in the longer term BioInvent is entitled to royalties on future net sales.
Latest news:
Is general: Yes
